Key Highlights

  • BluGlass received an A$1.4 million (US$1.0 million) Phase II contract from Uviquity and entered a further A$286,000 early-stage photonics collaboration.
  • An A$8.0 million Rockford R&D facility replaced the A$2.27 million Radium facility, adding about A$5.4 million of liquidity after refinancing.
  • Customer receipts were A$1.66 million and net operating cash outflow was A$3.12 million for the quarter.
  • Cash stood at A$8.66 million at 30 September 2026, with a A$6.1 million FY26 R&D Tax Incentive refund received in October.

BluGlass Limited (ASX:BLG), a vertically integrated developer and manufacturer of visible gallium nitride (GaN) lasers, has published its activities update and Appendix 4C for the three months ended 30 September 2026, the first quarter of FY27. The period combined new customer-funded development work with a larger research and development financing facility.

Chief Executive Officer and Managing Director Jim Haden said the company continued converting strategic customer engagement into funded development activity, including completing Year Three of its work under the U.S. Microelectronics Commons program.

Management presented at the iAccess Alpha Virtual Best Ideas Fall Investment Conference on 15 and 16 September, outlining priorities that include expanding share of the GaN laser market and growing U.S. government engagement. The 2026 Annual General Meeting was scheduled for 23 October in Sydney, where management planned to update shareholders on the quarter.

Customer-Funded Development Programs

In July, BluGlass received an A$1.4 million (US$1.0 million) Phase II contract from U.S. photonics company Uviquity under the companies' joint development agreement. Phase II extends the work beyond the first stage of research and development on Uviquity's integrated photonics platform to additional engineering, packaging, laser integration and purchases of BluGlass visible GaN lasers.

On 21 September, the company announced an early-stage collaboration worth about A$286,000 (US$200,000) with a global photonics leader to co-develop a novel GaN-based device for scientific and medical markets. The initial feasibility study is expected to run for three to five months and will assess the compatibility of the two companies' proprietary processes, covering device architectures, epitaxial structures, process integration and manufacturing techniques.

BluGlass also continued a multi-phase development with a Tier 1 U.S. defence prime and a collaboration with a Fortune 500 mass-capacity data-storage company. Activity during the quarter spanned epitaxial design and growth, device architecture evaluation, process integration, laser fabrication and packaging under what the company calls its project-to-product model.

The Rockford Financing Facility

In September, BluGlass agreed terms for an A$8.0 million R&D financing facility with Rockford RDF Pty Ltd, replacing the A$2.27 million Radium facility. After the refinancing, the facility provided approximately A$5.4 million of additional liquidity. It was fully drawn on 25 September 2026.

The facility bears interest of 16.5% per annum, capitalised daily, and carries a 2.5% establishment fee made up of A$100,000 capitalised into the loan and A$100,000 payable in BluGlass shares. The quarter-end balance, including capitalised fees and interest, was A$8.1 million, with no undrawn funding.

Security comprises first-ranking security over the FY26 and FY27 R&D Tax Incentive refunds, plus limited featherweight security over other assets. In October the company received its A$6.1 million FY26 refund and applied A$2.75 million to the scheduled loan repayment. The remaining balance is to be repaid from the FY27 refund and no later than 1 March 2028.

Quarterly Cash Flow

Receipts from customers were A$1.662 million. Operating payments included A$1.622 million for research and development excluding staff costs, A$2.233 million for staff costs, A$601,000 for administration and corporate costs, A$346,000 for leased assets and A$28,000 for advertising and marketing. Interest received was A$45,000, leaving net cash used in operating activities of A$3.123 million.

Investing activities used A$2.421 million, including A$271,000 for property, plant and equipment. Financing activities contributed A$2.922 million, reflecting A$8.0 million of borrowings less A$4.54 million of repayments, A$445,000 of loan transaction costs and A$93,000 of equity-related costs. Payments to related parties were A$114,000, comprising Executive Chair and non-executive director fees.

Cash and cash equivalents fell from A$11.343 million at the start of the quarter to A$8.655 million at quarter-end, after a A$66,000 exchange rate effect. The balance was split between A$8.613 million in bank balances and A$42,000 in call deposits.

Where the Numbers Leave the Company

BluGlass ended the quarter with A$8.655 million of cash and no unused facilities, which the Appendix 4C translates into an estimated 2.8 quarters of funding at the current operating outflow. The October tax refund of A$6.1 million, of which A$2.75 million went to the loan, followed quarter-end. On the governance side, Yam Rubenstein joined the Board as a non-executive director on 21 August, and Jim Haden was named Managing Director on 13 July. Mr Rubenstein is founder and CEO of 102 Percent Ltd and a co-founder of June 76 Investments, one of the company's largest shareholders.